Acción ARVN ARVINAS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Arvinas, Inc.

Acciones

ARVN

US04335A1051

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
31,77 USD -0,41 % Gráfico intradía de Arvinas, Inc. -6,56 % -22,81 %
24/04 Arvinas, Inc. nombra a Randy Teel director comercial CI
15/04 ARVINAS, INC. : HC Wainwright mantiene su recomendación de compra ZM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer
Arvinas : 2024 Proxy Statement
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Novartis : accord de licence dans le cancer de la prostate
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
Novartis étend sa recherche contre le cancer de la prostate
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten
Novartis licenses Arvinas' cancer drug for up to $1 billion
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
Arvinas Appoints Noah Berkowitz as Chief Medical Officer
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee
Arvinas to Participate in Upcoming Investor Conferences
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ARVN
  4. Noticias Arvinas, Inc.
  5. Otros idiomas